Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics
August 18 2020 - 8:00AM
Business Wire
Additional high-volume manufacturing line in
Colorado to produce high-quality molecules with potential for
treating cancer, COVID-19 and other diseases
Agilent Technologies Inc. (NYSE: A) today announced it will
expand its state-of-the-art production facility in Frederick,
Colorado, that develops and manufactures “oligos,” which are short
DNA and RNA molecules used to create nucleic acid-based
therapeutics. Oligos hold the potential to be used in developing
treatments for cancer, COVID-19, cardiovascular disease, rare and
infectious diseases, and other conditions. The expansion will more
than double the current capacity for manufacturing therapeutic
oligos at the Frederick site.
Agilent expects the supplier market for therapeutic oligos to
exceed $750 million in 2025 with projected double-digit annual
growth over the next five years. The addition of the higher-volume
manufacturing line will help Agilent meet this growing demand from
leading pharmaceutical and biotech companies. Customer shipments
from the new line are expected to begin by the end of 2022.
“We are excited about the ongoing growth of the therapeutic
oligo market and the continued strong interest in our oligo
contract development and manufacturing organization services from
existing and potential new customers,” said Sam Raha, president of
Agilent’s Diagnostics and Genomics Group. “Adding this
higher-volume line enables us to keep pace with demand while
continuing to deliver a premium product with superior customer
service. As a leading oligo manufacturer for more than 20 years,
Agilent is uniquely qualified to support this critical and growing
biopharma industry segment.”
Agilent is investing approximately $150 million to add 25,000
square feet of manufacturing capacity to the Frederick facility.
The new capacity will also expand Agilent’s presence in Colorado,
where the company has had an oligo manufacturing site in nearby
Boulder since 2006. The Frederick facility, 30 miles north of
Denver, has been operating since 2019. Both sites are current Good
Manufacturing Practices (cGMP) facilities, as designated by the
U.S. Food and Drug Administration.
“Today’s announcement reaffirms our commitment to Frederick and
the state of Colorado,” Raha added. “The addition of another
high-volume line will provide new jobs and new career opportunities
that are unique to the area.”
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200818005219/en/
Tom Beermann +1 408-553-2914 tom.beermann@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024